Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lifecore Biomedical (NASDAQ: LFCR) granted an inducement restricted stock unit (RSU) award covering 3,500 shares of common stock on July 13, 2026 under its Equity Inducement Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lifecore Biomedical (NASDAQ: LFCR) granted an inducement restricted stock unit (RSU) award covering 3,500 shares of common stock on July 13, 2026 under its Equity Inducement Plan. The award was made to a newly hired employee as a material inducement to join the company and was approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment, and are governed by an award agreement and the Inducement Plan.
Details
News Market Reaction – LFCR
On Jul 16, the first trading day after this news, LFCR closed 1.85% above the previous close. Argus tracked a peak move of +3.1% during that session. Our momentum scanner recorded 2 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 16 session.
Key Figures
- Restricted stock units
- 3,500 shares
- Inducement RSU grant to a newly hired employee under Inducement Plan
Historical Context
-
Signed tech transfer and commercial manufacturing deal for neurological disorder product.
-
New manufacturing services agreement for next-generation injectable ophthalmic product.
-
Management attending William Blair Growth Stock Conference and investor meetings.
-
Reported Q1 2026 results and reaffirmed full-year revenue and EBITDA guidance.
-
Scheduled Q1 2026 earnings release and webcast details for May 6, 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock unit financial
equity inducement plan financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHASKA, Minn., July 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on July 13, 2026, Lifecore granted a restricted stock unit (“RSU”) award with respect to 3,500 shares of its common stock under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) to a newly hired employee of Lifecore.
The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by Lifecore’s compensation committee and was granted as an inducement equity award in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.
The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The RSU award is governed by an award agreement and the Inducement Plan.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Lifecore Biomedical, Inc. Contact Information:
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com
Jennifer Arcure (Media)
917-603-0681
jarcure@vidasp.com
Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
ryan.lake@lifecore.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.